Understanding Cancer: Preventing and Lowering Your Risk | Joe Zundell PhD

Both Lyon and Zundell speak from personal loss — Zundell's mother and Lyon's stepdad both died of esophageal cancer that was detected too late. Lyon's clinical network caught an esophageal cancer signal via Grail in a veteran who had negative visual evaluation. The screening protocol conversation is grounded in this lived experience, not just epidemiology. Zundell's core argument: we invest in vaccines as universal public health tools; cancer early detection tests should be treated with the same universal-access logic.

Zundell emphasizes that skeletal muscle mass is physically intertwined with the lymphatic system — muscle contraction drives lymphatic fluid movement, which is the highway for immune surveillance. This creates a mechanistic bridge from muscle activity to immune function. The IL-15 data from mouse models adds a specific cytokine mechanism on top of the structural lymphatic benefit. For cancer prevention, reducing visceral fat also reduces the metabolic disruption (altered insulin-glucagon balance, increased liver stress) that Zundell links to liver, colon, gallbladder, and breast cancers among the CDC's 13 obesity-linked cancer types.

Zundell notes a surge in oncology-setting recommendations for increased exercise and protein — a shift from the previously more passive nutritional approach to cancer care. He credits this to growing cachexia research showing that muscle preservation correlates with treatment tolerance and survival. The protein-cancer myth he addresses stems from observations that cancers alter glutaminase expression and amino acid metabolism (including his own published work on glutamine metabolism) — which creates a superficially plausible but causally incorrect link between dietary protein and cancer promotion.

Zundell notes that Mexico labels alcohol with bold cancer warnings at the airport — a policy he endorses as a public health intervention the United States lacks. His argument mirrors the tobacco normalization shift: once tobacco was culturally denormalized and carcinogen warnings were mandatory, consumption patterns shifted at a population level. He sees no scientific reason alcohol should be treated differently from a public health communication standpoint.

Zundell separates himself from the popular online claim that red meat causes cancer. He identifies the mechanism precisely: amino acid breakdown at high temperatures produces HCAs and PAHs. He notes the NCI has released formal guidance on this. His own dietary practice: high red meat consumption overall, charred preparation limited to roughly once weekly. The pairing of red meat with a diverse vegetable-rich diet is key — the claim that red meat in isolation causes cancer ignores the dietary context in which it is consumed.

Zundell's friend with Lynch syndrome prompted this discussion. He notes that Lynch carriers need to eat a ton of fiber as part of their lifestyle management — fiber's role in reducing colonic inflammatory signaling provides partial offset to the DNA repair deficiency that underlies Lynch syndrome. He also notes that even in clearly genetic syndromes, environmental and metabolic factors interact with the genetic predisposition — reinforcing the both/and framing of cancer causation.

Zundell recounts a mentor who had breast cancer, declined chemotherapy and radiation, pursued alternative clinics and dietary protocols, and died quickly. He acknowledges the emotional logic — fear, desire for control, belief in the body's healing capacity — without validating the clinical choice. He notes that some supplements (NAD, certain herbal compounds) could actively worsen cancer outcomes depending on the tumor type.

Zundell's early research focused on chronic lymphocytic leukemia (CLL) and the endoplasmic reticulum (ER) stress response — a pathway both normal B cells and CLL cancer cells use, which is why drugs targeting it tend to be too toxic for clinical use. The broader lesson: because cancer cells are derived from host cells, they share almost all of the same survival pathways. Specificity is incredibly hard to achieve. The clonal evolution insight also explains why multi-drug combinations — which target multiple subpopulations simultaneously — outperform single agents even when the single agent shows initial efficacy.

The distinction matters practically: a family that understands remission as a temporary suppression — not eradication — will maintain surveillance, continue lifestyle modifications, and be psychologically prepared for recurrence. A family that believes remission equals cure will be blindsided and may defer subsequent monitoring. Lyon's stepdad returned with irretractable back pain — a late metastatic signal — having been assumed cancer-free.

Zundell notes the IL-15 finding was recently published and he released a social media post on it. For cancer patients specifically, the conventional concern has been about energy depletion and cachexia risk from exercise — the IL-15 data provide a rationale for maintaining moderate exercise even in active cancer treatment. The practical message: for both prevention and active patients, reducing sedentary time and preserving skeletal muscle mass serve dual purposes — metabolic and immunological.

Zundell is careful to emphasize this is emerging evidence, not clinical guidance. Cancer patients who start a ketogenic diet without oncologist involvement risk interfering with ongoing treatment or worsening cachexia — the hyper-catabolic wasting that already threatens most late-stage patients. The window concept means the diet should ideally be timed with — or tested in clinical trials against — the specific chemotherapeutic regimen. Pancreatic cancer was the model precisely because standard-of-care outcomes are so poor that novel combinations are being aggressively investigated.

Zundell's published work on ER stress in CLL and on NAD metabolism in ovarian cancer illustrates the same underlying problem: cancer cells co-opt normal cellular metabolic infrastructure. Supplementing a pathway that normal aging depletes may simultaneously fuel a cancer that has learned to exploit the same pathway. This does not mean NAD supplements are dangerous for everyone — it means cancer patients should not assume any supplement is categorically safe without oncologist review.

Zundell himself limits charred steak to roughly one per week and acknowledges eating more red meat than optimal, but frames a weekly charred steak as a reasonable tradeoff within an otherwise varied diet. The key caveat: if red meat is the predominant food group, the carcinogen load compounds without the offsetting effects of fiber, vegetables, and other dietary elements. The NCI has published formal guidance on heterocyclic amine formation with cooking temperature and time.

The esophageal cancer case in the episode: a soldier in Lyon's network had swallowing difficulties and a sensation but no visual abnormality on evaluation. Grail test was positive. Zundell does not know the outcome. Lyon's own stepdad — and Zundell's mother — both died of esophageal cancer, a disease notorious for late-stage detection. Both advocate strongly for universal access to tests like Grail as a public health intervention, arguing they should be covered the way vaccines are. Zundell frames the cost-benefit: catching any cancer early, regardless of type, dramatically enhances survival.

Cachexia is a state where catabolism (breakdown) dramatically exceeds anabolism (building). Muscle wasting accelerates, body weight drops, and patients' ability to tolerate aggressive treatment diminishes. Adding fasting to this state would accelerate muscle loss, worsen treatment tolerance, and potentially shorten survival. The nuance: theoretical fasting-induced metabolic windows may exist for early, nutritionally stable patients in controlled clinical trial settings — but this is not a population-level recommendation.